{{ref improve|date=August 2014}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477316351
| IUPAC_name = 7-[(1''R'',5''S'')-6-<nowiki/>{[(2''S'')-1-<nowiki/>{[(2''S'')-2-Aminopropanoyl]amino}-1-oxopropan-2-yl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
| image = Alatrofloxacin.svg
| width = 250

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CONS|alatrofloxacin}}
| MedlinePlus = a605016
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Withdrawn
| routes_of_administration = [[Intravenous therapy|Intravenous]]

<!--Pharmacokinetic data-->
| bioavailability = N/A
| protein_bound = 76% (trovafloxacin)
| metabolism = Quickly [[hydrolysis|hydrolyzed]] to [[trovafloxacin]]
| elimination_half-life = 9 to 12 hours (trovafloxacin)
| excretion = Fecal and [[kidney|renal]] (trovafloxacin)

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 146961-76-4
| ATC_prefix = none
| ATC_suffix =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 21243647
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7QVV6I50DT
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201197

<!--Chemical data-->
| C=26 | H=25 | F=3 | N=6 | O=5 
| molecular_weight = 558.509 g/mol

|  smiles = C[C@@H](C(=O)N[C@@H](C)C(=O)N[C@H]1[C@H]2[C@@H]1CN(C2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F)N
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C26H25F3N6O5/c1-10(30)24(37)31-11(2)25(38)32-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)33-23)19-4-3-12(27)5-17(19)28/h3-6,9-11,14-15,20H,7-8,30H2,1-2H3,(H,31,37)(H,32,38)(H,39,40)/t10-,11-,14-,15+,20+/m0/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = UUZPPAMZDFLUHD-VUJLHGSVSA-N
}}

'''Alatrofloxacin''' ('''Trovan IV''') is a [[fluoroquinolone antibiotic]] developed by [[Pfizer]], delivered as a [[mesylate]] [[salt (chemistry)|salt]].<ref>{{cite web|title=Center for Drug Evaluation and Research {{ndash}} Application Number: 020759/020760 {{ndash}} Chemistry Review(s)|publisher=[[Food and Drug Administration]]|url=http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a_chemr.pdf|accessdate=29 August 2014}}</ref>

Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.

==See also==
* [[Adverse effects of fluoroquinolones]]

==References==
<references />

{{QuinoloneAntiBiotics}}

[[Category:Fluoroquinolone antibiotics]]
[[Category:Prodrugs]]
[[Category:Hepatotoxins]]
[[Category:Withdrawn drugs]]
[[Category:Naphthyridines]]
[[Category:Carboxylic acids]]


{{antibiotic-stub}}